Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

Simple Summary The use of novel therapeutic drugs in lung cancer has changed the
paradigm of the diagnosis and treatment of lung cancer. Due to the development of …

Lung cancer accounts for a quarter of all cancer deaths. Non-small cell lung cancer
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

Lung cancer remains the leading cause of cancer-related death in men and women, despite
its constantly declining rates in incidence and mortality in the developed world. The past …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Introduction: The discovery of new actionable oncogenic drivers has led to the development
of effective antineoplastic targeted agents in advanced non-small cell lung cancer (NSCLC) …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has
undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal …